Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Cancers 2013, 5(3), 901-918; doi:10.3390/cancers5030901
Article

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

1
, 1,2,3
, 1
, 1
, 1
, 1
, 4
, 4,†
, 2,3,*  and 1,*
Received: 5 June 2013; in revised form: 4 July 2013 / Accepted: 4 July 2013 / Published: 24 July 2013
(This article belongs to the Special Issue Kinases and Cancer)
View Full-Text   |   Download PDF [734 KB, uploaded 24 July 2013]
Abstract: Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma.
Keywords: apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Natoni, A.; Coyne, M.R.E.; Jacobsen, A.; Rainey, M.D.; O'Brien, G.; Healy, S.; Montagnoli, A.; Moll, J.; O'Dwyer, M.; Santocanale, C. Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. Cancers 2013, 5, 901-918.

AMA Style

Natoni A, Coyne MRE, Jacobsen A, Rainey MD, O'Brien G, Healy S, Montagnoli A, Moll J, O'Dwyer M, Santocanale C. Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. Cancers. 2013; 5(3):901-918.

Chicago/Turabian Style

Natoni, Alessandro; Coyne, Mark R.E.; Jacobsen, Alan; Rainey, Michael D.; O'Brien, Gemma; Healy, Sandra; Montagnoli, Alessia; Moll, Jürgen; O'Dwyer, Michael; Santocanale, Corrado. 2013. "Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models." Cancers 5, no. 3: 901-918.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert